Cas:842972-09-2 5-fluoro-3-methyl-1h-indole-2-carbaldehyde manufacturer & supplier

We serve Chemical Name:5-fluoro-3-methyl-1h-indole-2-carbaldehyde CAS:842972-09-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-fluoro-3-methyl-1h-indole-2-carbaldehyde

Chemical Name:5-fluoro-3-methyl-1h-indole-2-carbaldehyde
CAS.NO:842972-09-2
Synonyms:5-fluoro-3-methyl-1h-indole-2-carbaldehyde
Molecular Formula:C10H8FNO
Molecular Weight:177.17500
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:347.7ºC at 760 mmHg
Density:1.322g/cm3
Index of Refraction:1.67
PSA:32.86000
Exact Mass:177.05900
LogP:2.42790

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 5-fluoro-3-methyl-1h-indole-2-carbaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-fluoro-3-methyl-1h-indole-2-carbaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-fluoro-3-methyl-1h-indole-2-carbaldehyde Use and application,5-fluoro-3-methyl-1h-indole-2-carbaldehyde technical grade,usp/ep/jp grade.


Related News: So-called “off” periods occur when a Parkinson’s patient has difficulty moving about and occur when the effect of the last dose of another common Parkinson’s drug, known as levodopa, wears off. 1-methylindole-3-carbonyl chloride manufacturers This announcement follows earlier expansions at the Ballina site where additional Good Manufacturing Practice (GMP) facilities and capabilities have been added in analytical, cell culture, vaccine support and other specialised Biologics services. 4-naphthalen-2-ylpiperidine,hydrochloride suppliers Biogen hiked its revenue guidance for the year, saying it expects total sales of $10.65 billion to $10.85 billion this year. That’s up from its previous estimates of $10.45 billion to $10.75 billion. The new forecast assumes “modest” revenue from Aduhelm in 2021, ramping up thereafter, the company said. N-[(8α,9S)-Cinchonan-9-yl]-2-pyridinecarboxamide vendor & factory.